Yes — an AMH of 0.5 ng/mL means low ovarian reserve, not a closed door: women under 35 with AMH 0.5–1.2 still achieve 25–35% live birth per IVF cycle, rising to 55–65% across three cycles. The path there runs through the right stimulation protocol, correctly timed adjuncts like DHEA and CoQ10, and a clinic that routinely handles low egg yields.
What Does an AMH of 0.5 Actually Mean?
The first thing to separate is quantity from quality: AMH predicts how many eggs stimulation will yield, not whether those eggs can make a baby.
AMH (Anti-Müllerian Hormone) is produced by pre-antral and small antral follicles and directly reflects the size of your remaining follicle pool. Its clinical value is predicting ovarian response to stimulation — how many eggs retrieval will find. It does not directly predict egg quality, which is governed mainly by age (ASRM Committee Opinion, Fertility and Sterility, 2020). Under the POSEIDON classification, AMH below 1.2 ng/mL marks low reserve, so 0.5 places you in the low-responder groups — but low reserve is not zero reserve.
AMH Reference Ranges and POSEIDON Grouping
| AMH (ng/mL) | Ovarian Reserve | Expected Response | POSEIDON Group |
|---|---|---|---|
| > 2.0 | Normal | Good (8–15+ eggs) | N/A |
| 1.2 – 2.0 | Borderline low | Moderate (5–8 eggs) | Possible Group 3 |
| 0.5 – 1.2 | Low | High risk of poor response (1–4 eggs) | POSEIDON 3/4 |
| < 0.5 | Severely low | Very poor or no response | POSEIDON 4 |
Data: Broer et al., Human Reproduction Update, 2014; POSEIDON criteria, Alviggi et al., Fertility and Sterility, 2016.
With AMH 0.5 you will most likely retrieve 1–4 eggs per stimulation, but once a usable embryo exists, live-birth odds are not far behind normal-reserve patients — provided the embryo is chromosomally normal.
“Antimüllerian hormone (AMH) level is strongly associated with ovarian response in assisted reproductive technology (ART) cycles but is a poor predictor of live birth.” — Tal et al., Journal of Clinical Endocrinology and Metabolism, 2021, DOI
Broer’s review of ovarian reserve testing (Human Reproduction Update, 2014) and a 715-cycle prediction-model analysis (Rongieres et al., Journal of Assisted Reproduction and Genetics, 2015) reach the same conclusion: AMH predicts egg count well, but “the added predictive value of AMH is limited” once age and other baseline variables are in the model.
In short: low AMH mainly affects whether you can retrieve eggs, not whether those eggs can become a baby — especially under age 38.
What Are the Real Success Rates with AMH 0.5?
Single-cycle live birth with AMH 0.5–1.2 ranges from 25–35% under 35 down to 6–12% over 40, with AMH below 0.5 sitting one band lower.
| Age Group | AMH 0.5–1.2 per Cycle | AMH < 0.5 per Cycle | Notes |
|---|---|---|---|
| Under 35 | 25–35% | 15–25% | Egg quality still good despite low count |
| 35–37 | 18–28% | 10–18% | Age factor starts compounding |
| 38–40 | 12–20% | 6–12% | Quality and quantity challenges |
| Over 40 | 6–12% | 3–6% | Strongly consider donor eggs |
Data: SART 2023 National Summary Report plus low-reserve cohort studies.
Cumulative Live Birth Rate — The Number That Actually Matters
For low-reserve patients, single-cycle statistics underestimate your real odds, because 2–4 retrievals are often needed to bank enough embryos for transfer.
| Cycles | Under 38 / AMH 0.5–1.2 | 38–40 / AMH 0.5–1.2 |
|---|---|---|
| 1 cycle | 25–35% | 12–20% |
| 2 cycles cumulative | 45–55% | 22–32% |
| 3 cycles cumulative | 55–65% | 30–40% |
How these ranges were built: the per-cycle column carries forward the age-stratified live-birth rates above (SART 2023 national summary), and the cumulative column applies the standard independent-cycle accumulation formula (1-(1-p)^n) and then discounts it, because low-reserve patients frequently drop out before a transfer is possible. They are ranges for counselling, not personal prognosis. That AMH itself matters for accumulation is supported by a SART database analysis of 34,540 retrieval cycles with AMH < 1 ng/mL: AMH was an independent predictor of cumulative live birth (OR 1.39, 95% CI 1.18–1.64) and correlated with cumulative live birth within every age stratum (Tal et al., Journal of Clinical Endocrinology and Metabolism, 2021).
Individual results also depend on surgical history (especially ovarian cystectomy), BMI and — critically — the clinic’s embryology lab. Our guide to choosing an IVF clinic details what to verify.
Which Stimulation Protocol Works Best for Low Reserve?
Protocol choice matters far more with AMH 0.5 than with normal reserve — the wrong protocol can cancel an entire cycle.
| Protocol | Best For | Avg Eggs | Cost per Cycle (USD) | Key Advantage | Evidence |
|---|---|---|---|---|---|
| Antagonist | POSEIDON 3/4 | 2–5 | $8,000–$14,000 | Flexible, dose-adjustable | ★★★★★ |
| Mild (clomiphene + low-dose FSH) | AMH < 0.5 | 1–3 | $4,000–$7,000 | Cheap, zero OHSS risk, repeatable back-to-back | ★★★★ |
| Natural cycle | One follicle per month | 0–1 | $3,000–$5,000 | No medication, monthly repetition | ★★★ |
| DuoStim | Time-pressed, older low-reserve | 2–3 × 2 | $12,000–$20,000 | Two retrievals in one cycle | ★★★ |
| Luteal-phase stimulation | Poor follicular response | 1–3 | $8,000–$14,000 | Extra retrieval window | ★★★ |
Mild stimulation: the case for it rests on drug dose and cost, not on a demonstrated live-birth advantage. A multicenter randomized non-inferiority trial of 394 women (Human Reproduction, 2017) compared mild stimulation — 150 IU FSH with a GnRH antagonist — against conventional stimulation (450 IU HMG with a long mid-luteal agonist protocol) in women aged ≥ 35 or with poor ovarian reserve. Ongoing pregnancy was 12.8% versus 13.6% (RR 0.95, 95% CI 0.57–1.57), with the confidence interval staying above the pre-set 10% non-inferiority threshold; mild stimulation used 1.2 fewer stimulation days (95% CI −1.88 to −0.62) and 3,135 IU less gonadotropin (95% CI −3,331 to −2,940). The same trial did not track frozen embryo transfers and could not follow every centre to delivery, so it yields no cumulative live-birth figure — treat any “four mild cycles equal two conventional cycles” claim as arithmetic, not evidence.
Natural cycle IVF: with AMH under 0.5 and one visible follicle monthly, per-cycle live birth is roughly 7–10%, but six uninterrupted cycles accumulate to 30–40% (Morgia et al., Fertility and Sterility, 2021), with zero drugs and zero OHSS risk at $3,000–$5,000 per cycle.
DuoStim: a ten-year single-center experience of 1,896 DuoStim cycles in 1,656 poor-prognosis patients (Frontiers in Endocrinology, 2026; poor prognosis defined as age ≥ 40 and/or AMH ≤ 1.2 ng/mL, AFC ≤ 5, or ≤ 3 oocytes previously retrieved) found the second stimulation yielded more oocytes and embryos than the first while embryo competence stayed comparable. Relative to the first stimulation alone, the second retrieval raised the number of cycles reaching at least one euploid blastocyst by 66% and those reaching a live birth by 125%, with a cumulative live-birth rate of 28.5% per concluded first DuoStim cycle.
For how each protocol actually runs day by day, see IVF process step by step.
Do DHEA and CoQ10 Actually Help?
CoQ10 has moderate backing as an adjunct for low reserve, while the latest Cochrane evidence on DHEA is far less encouraging — and neither replaces a well-chosen stimulation protocol.
| Agent | Mechanism | Best For | Evidence | Typical Use |
|---|---|---|---|---|
| DHEA | Raises androgen levels, aids follicle recruitment | AMH < 1.0, especially under 38 | ★ (Cochrane 2024: no clear live-birth gain) | 25 mg three times daily, 8–12 weeks pretreatment |
| CoQ10 (ubiquinol) | Improves egg mitochondrial function | Age 35+, low reserve | ★★★★ | 200–600 mg daily, 3 months pretreatment |
| Growth hormone | Synergises with FSH on granulosa cells | POSEIDON 3/4 | ★★★ | During stimulation |
| Melatonin | Antioxidant, follicular environment | Poor egg quality | ★★ | 2–4 mg at bedtime |
| Vitamin D | AMH receptor modulation | Patients with vitamin D deficiency | ★★ | Supplement to sufficient blood levels |
DHEA: the 2024 Cochrane review of 28 RCTs in poor responders found 25 mg three times daily for 8–12 weeks made little to no difference to live birth (OR 1.30, 95% CI 0.95–1.76) or clinical pregnancy (OR 1.18, 95% CI 0.93–1.49) versus placebo, whereas testosterone pretreatment did improve live birth (OR 2.53, 95% CI 1.61–3.99). Some clinics still trial DHEA where androgens are low, but benefit is unproven over 40 and DHEA is not appropriate with PCOS.
CoQ10: Bentov et al. (2020) showed 400 mg daily for 3 months significantly improved mitochondrial energy metabolism in cumulus cells, and a 2023 meta-analysis of 7 RCTs (842 patients) found higher clinical pregnancy rates versus placebo (RR 1.44, 95% CI 1.10–1.88).
Dosing and timing must be set by your reproductive specialist from your AMH, age and cycle history; our IVF preparation checklist covers the full pretreatment routine.
How Do You Choose a Clinic for Low Ovarian Reserve?
The same AMH 0.5 patient can face a 40% cycle-cancellation rate at one clinic and 15% at another that specialises in low reserve.
| Criterion | Key Question to Ask | Why It Matters |
|---|---|---|
| Mild/natural-cycle experience | Do you run these protocols routinely? | Low reserve demands flexible switching |
| Cycle cancellation rate | What share of cycles is cancelled for poor response? | Reveals true individualisation |
| ICSI technique | Is Piezo-ICSI standard? | With 1–2 eggs, none can be wasted |
| Lab outcomes | Are blastocyst formation and freeze-thaw survival published? | Few eggs must become quality embryos |
| Multi-cycle packages | 2–3 cycle bundles or refund programs? | Multiple cycles are the norm |
| Language support | Native-language patient coordinator? | Directly affects communication quality |
Clinics with the deepest mild-stimulation and low-yield experience cluster in parts of Japan and the US. Compare what different countries charge for these protocols in our IVF cost guide 2026, and see USA vs Thailand IVF for protocol and legal differences.
When Should You Consider Donor Eggs?
The donor-egg decision tracks your age and embryo quality, not the AMH number itself.
| Profile | Recommended Path | Rationale |
|---|---|---|
| Under 38, AMH 0.5, no prior IVF | 2–3 own-egg cycles (mild/antagonist) | Age compensates for low count |
| 38–40, AMH 0.5, or eggs but no usable embryos | Own eggs plus parallel donor assessment | Backup does not delay the primary plan |
| Over 40, AMH 0.5 | Seriously consider donor eggs | Count and euploidy both working against you |
| 2–3 cycles with no usable embryos | Transition to donor eggs | Egg quality is now the limiting factor |
For freezing options and the legal landscape around donor gametes, see our egg freezing guide.
FAQ
Q: Does AMH 0.5 mean menopause is close?
No. AMH 0.5 confirms significantly reduced reserve, but the interval from this level to menopause varies from roughly 5 to 10 years between women.
If you want children, though, start IVF now rather than waiting (ASRM Committee Opinion, Fertility and Sterility, 2020).
Q: Do I need PGT-A with AMH 0.5?
The value depends on age, not AMH. Under 35, euploidy rates match normal-reserve patients and PGT-A adds little; over 38, aneuploidy rises sharply, and when only 1–2 blastocysts exist, prioritising the euploid one is critical.
Details in our PGT genetic screening guide.
Q: Can treatment raise my AMH back up?
No test or therapy enlarges the remaining follicle pool. DHEA may lift the measured value by 0.2–0.5 ng/mL by recruiting small antral follicles, but no new eggs are created — treat any clinic advertising “reversed ovarian age” with skepticism.
Q: Is low AMH IVF only possible abroad?
No — clinics experienced with low reserve operate in mainland China, Japan, Thailand and the US. The deciding factor is the centre’s mild-stimulation track record, not the country, though costs differ widely: $10,000–$25,000 per cycle in the US versus $5,000–$10,000 in Thailand.
See the IVF cost guide 2026.
Q: If I only retrieve 1–2 eggs, was the cycle wasted?
Not necessarily. For patients under 35, even 2 retrieved eggs carry a 30–50% chance of one good blastocyst.
The core low-reserve strategy is accumulation: freeze embryos across 2–3 retrievals, then transfer once enough are banked, which markedly raises per-transfer success.
References
- ASRM Practice Committee, 2020. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility, 114(6):1203–1213. asrm.org
- Alviggi C, et al. (2016). A new more detailed stratification of low responders to ovarian stimulation. Fertility and Sterility, 105(6):1452–1453. DOI: 10.1016/j.fertnstert.2016.02.005
- Broer SL, Broekmans FJ, Laven JS, Fauser BC. (2014). Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update, 20(5):688–701. DOI: 10.1093/humupd/dmu020
- Naik S, Lepine S, Nagels HE, Siristatidis CS, Kroon B, McDowell S. (2024). Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews, 2024(6):CD009749. DOI: 10.1002/14651858.CD009749.pub3
- Youssef MA, van Wely M, Al-Inany H, et al. (2017). A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Human Reproduction, 32(1):112–118. DOI: 10.1093/humrep/dew282
- Rongieres C, Colella C, Lehert P. (2015). To what extent does Anti-Mullerian Hormone contribute to a better prediction of live birth after IVF? Journal of Assisted Reproduction and Genetics, 32(1):37–43. DOI: 10.1007/s10815-014-0348-3
- Tal R, Seifer DB, Tal R, Granger E, Wantman E, Tal O. (2021). AMH highly correlates with cumulative live birth rate in women with diminished ovarian reserve independent of age. Journal of Clinical Endocrinology and Metabolism, 106(9):2754–2766. DOI: 10.1210/clinem/dgab168
- Ubaldi FM, Innocenti F, Taggi M, et al. (2026). Ten years of DuoStim in time-sensitive poor-prognosis IVF patients: real world cumulative outcomes and treatment trajectories. Frontiers in Endocrinology, 17:1854570. DOI: 10.3389/fendo.2026.1854570
- SART. (2023). National Summary Report. Society for Assisted Reproductive Technology. sart.org
Next Steps
AMH 0.5 changes the odds, not the possibility — the plan that wins is protocol matching, multi-cycle accumulation and a lab proven with low yields. Shortlist clinics using the checklist above, request their cancellation and blastocyst rates, and start the conversation early.
Compare fertility clinics in our hospital directory or contact our advisory team for a personalised review of your results.
About this article: researched and written by the ProIVF Medical Editorial Team from ASRM committee opinions, Cochrane systematic reviews and peer-reviewed literature listed above, and reviewed by the ProIVF Medical Advisory Board. Statistics are population-level references and do not predict individual outcomes — confirm your prognosis with a reproductive specialist. This article is for informational purposes only and is not medical advice. Editorial standards: ProIVF About page. Last updated: 2026-09-20.
